Patients were of a median age of 51 years old – 78% with SCC and 22% with adenocarcinoma or adenosquamous carcinoma – and randomised to receive 350mg Libtayo every three weeks or chemotherapy ...

Now, Libtayo (cemiplimab) is also in the mix. Sanofi and Regeneron have just halted a 466-patient phase 3 trial of the drug in combination with chemo rarely, saying they saw a significant ...

The Nonmelanoma Skin Cancer market is expected to experience substantial growth from 2024 to 2034, driven by increasing ...

Sequencing the novel drug, THIO, with Libtayo tended to be tolerable in patients with ... a clinical trial evaluating a reduced dose of post-transplant immunosuppressive chemotherapy cyclophosphamide ...

Panelists discuss how the five-year prognosis for advanced non-small cell lung cancer (NSCLC) has improved with PD-1 inhibitors, showing promising overall survival (OS) and progression-free survival ...

Libtayo shows robust growth in specific cancers, although it faces stiff competition in broader indications, highlighting Regeneron’s ability to develop blockbuster drugs. Regeneron appears ...

today announced that Ig - Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data ...

Panelists discuss how, at their practices, histology, staging and ECOG performance status guide treatment decisions for advanced non-small cell lung cancer (NSCLC). Compared with EMPOWER-Lung 1, these ...

Heartburn and acid reflux are common during chemotherapy ("chemo"), caused by cancer drugs subsequently attacking cells of the stomach and esophagus (feeding tube). Symptoms can flare immediately ...

Chemotherapy is a treatment used to kill cancer cells. It involves taking one or more of a type of drug that interferes with the DNA of fast-growing cells. These drugs are subdivided into specific ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 176,000 newsletter subscribers for 21 days.